Cargando…

Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients

INTRODUCTION: The outcomes of osteosarcoma in low middle income countries (LMICs) are different due to patients presenting in advanced stages, resource constraints and the use of non-high-dose-methotrexate (HDMTX)-based regimens. This study derived and validated a prognostic score for osteosarcoma t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganguly, Shuvadeep, Sasi, Archana, Khan, Shah Alam, Kumar, Venkatesan Sampath, Kapoor, Love, Sharma, Mehar Chand, Mridha, Asit, Barwad, Adarsh, Thulkar, Sanjay, Pushpam, Deepam, Bakhshi, Sameer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175811/
https://www.ncbi.nlm.nih.gov/pubmed/37188186
http://dx.doi.org/10.3389/fonc.2023.1148480
_version_ 1785040293239717888
author Ganguly, Shuvadeep
Sasi, Archana
Khan, Shah Alam
Kumar, Venkatesan Sampath
Kapoor, Love
Sharma, Mehar Chand
Mridha, Asit
Barwad, Adarsh
Thulkar, Sanjay
Pushpam, Deepam
Bakhshi, Sameer
author_facet Ganguly, Shuvadeep
Sasi, Archana
Khan, Shah Alam
Kumar, Venkatesan Sampath
Kapoor, Love
Sharma, Mehar Chand
Mridha, Asit
Barwad, Adarsh
Thulkar, Sanjay
Pushpam, Deepam
Bakhshi, Sameer
author_sort Ganguly, Shuvadeep
collection PubMed
description INTRODUCTION: The outcomes of osteosarcoma in low middle income countries (LMICs) are different due to patients presenting in advanced stages, resource constraints and the use of non-high-dose-methotrexate (HDMTX)-based regimens. This study derived and validated a prognostic score for osteosarcoma that integrates biologic and social factors and is tailored for patients from an LMIC setting using a non-HDMTX-based protocol. MATERIALS AND METHODS: A retrospective study including osteosarcoma patients enrolled for treatment at a single tertiary care centre in India between 2003-19 was conducted. Baseline biologic and social characteristics were extracted from medical records and survival outcomes were noted. The cohort was randomised into a derivation and validation cohort. Multivariable Cox regression was used to identify baseline characteristics that were independently prognostic for survival outcomes in the derivation cohort. A score was derived from the prognostic factors identified in the derivation cohort and further validated in the validation cohort with estimation of its predictive ability. RESULTS: 594 patients with osteosarcoma were eligible for inclusion in the study. Around one-third of the cohort had metastatic disease with 59% of the patients residing in rural areas. The presence of metastases at baseline (HR 3.39; p<0.001; score=3), elevated serum alkaline phosphatase (SAP) >450 IU/L (HR 1.57; p=0.001; score=1) and baseline tumour size > 10 cm (HR 1.68; p<0.001; score=1) were identified to be independent factors predicting inferior event free survival (EFS) and were included in development of the prognostic score. Patients were categorized as low risk (score 0), intermediate risk (score 1-3) and high risk (4-5). Harrell’s c-indices for the score were 0.682, 0.608 and 0.657 respectively for EFS in the derivation, validation and whole cohort respectively. The timed AUC of ROC was 0.67 for predicting 18-month EFS in the derivation, validation and whole cohorts while that for 36-month EFS were 0.68, 0.66 and 0.68 respectively. CONCLUSIONS: The study describes the outcomes among osteosarcoma patients from an LMIC treated uniformly with a non-HDMTX-based protocol. Tumor size, baseline metastases and SAP were prognostic factors used to derive a score with good predictive value for survival outcomes. Social factors did not emerge as determinants of survival.
format Online
Article
Text
id pubmed-10175811
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101758112023-05-13 Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients Ganguly, Shuvadeep Sasi, Archana Khan, Shah Alam Kumar, Venkatesan Sampath Kapoor, Love Sharma, Mehar Chand Mridha, Asit Barwad, Adarsh Thulkar, Sanjay Pushpam, Deepam Bakhshi, Sameer Front Oncol Oncology INTRODUCTION: The outcomes of osteosarcoma in low middle income countries (LMICs) are different due to patients presenting in advanced stages, resource constraints and the use of non-high-dose-methotrexate (HDMTX)-based regimens. This study derived and validated a prognostic score for osteosarcoma that integrates biologic and social factors and is tailored for patients from an LMIC setting using a non-HDMTX-based protocol. MATERIALS AND METHODS: A retrospective study including osteosarcoma patients enrolled for treatment at a single tertiary care centre in India between 2003-19 was conducted. Baseline biologic and social characteristics were extracted from medical records and survival outcomes were noted. The cohort was randomised into a derivation and validation cohort. Multivariable Cox regression was used to identify baseline characteristics that were independently prognostic for survival outcomes in the derivation cohort. A score was derived from the prognostic factors identified in the derivation cohort and further validated in the validation cohort with estimation of its predictive ability. RESULTS: 594 patients with osteosarcoma were eligible for inclusion in the study. Around one-third of the cohort had metastatic disease with 59% of the patients residing in rural areas. The presence of metastases at baseline (HR 3.39; p<0.001; score=3), elevated serum alkaline phosphatase (SAP) >450 IU/L (HR 1.57; p=0.001; score=1) and baseline tumour size > 10 cm (HR 1.68; p<0.001; score=1) were identified to be independent factors predicting inferior event free survival (EFS) and were included in development of the prognostic score. Patients were categorized as low risk (score 0), intermediate risk (score 1-3) and high risk (4-5). Harrell’s c-indices for the score were 0.682, 0.608 and 0.657 respectively for EFS in the derivation, validation and whole cohort respectively. The timed AUC of ROC was 0.67 for predicting 18-month EFS in the derivation, validation and whole cohorts while that for 36-month EFS were 0.68, 0.66 and 0.68 respectively. CONCLUSIONS: The study describes the outcomes among osteosarcoma patients from an LMIC treated uniformly with a non-HDMTX-based protocol. Tumor size, baseline metastases and SAP were prognostic factors used to derive a score with good predictive value for survival outcomes. Social factors did not emerge as determinants of survival. Frontiers Media S.A. 2023-04-28 /pmc/articles/PMC10175811/ /pubmed/37188186 http://dx.doi.org/10.3389/fonc.2023.1148480 Text en Copyright © 2023 Ganguly, Sasi, Khan, Kumar, Kapoor, Sharma, Mridha, Barwad, Thulkar, Pushpam and Bakhshi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ganguly, Shuvadeep
Sasi, Archana
Khan, Shah Alam
Kumar, Venkatesan Sampath
Kapoor, Love
Sharma, Mehar Chand
Mridha, Asit
Barwad, Adarsh
Thulkar, Sanjay
Pushpam, Deepam
Bakhshi, Sameer
Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
title Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
title_full Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
title_fullStr Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
title_full_unstemmed Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
title_short Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
title_sort formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175811/
https://www.ncbi.nlm.nih.gov/pubmed/37188186
http://dx.doi.org/10.3389/fonc.2023.1148480
work_keys_str_mv AT gangulyshuvadeep formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT sasiarchana formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT khanshahalam formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT kumarvenkatesansampath formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT kapoorlove formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT sharmameharchand formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT mridhaasit formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT barwadadarsh formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT thulkarsanjay formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT pushpamdeepam formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients
AT bakhshisameer formulationandvalidationofabaselineprognosticscoreforosteosarcomatreateduniformlywithanonhighdosemethotrexatebasedprotocolfromalowmiddleincomehealthcaresettingasinglecentreanalysisof594patients